An Open-label Comparative Study of the Pharmacokinetics, Safety and Tolerability of ZD4054 following a 10 mg Single Oral Dose of ZD4054 to Healthy Subjects and to Subjects with Mild, Moderate and Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2014
At a glance
- Drugs Zibotentan (Primary)
- Indications Breast cancer; Colorectal cancer; Prostate cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 06 Mar 2009 Actual end date reported as 1 Mar 09 by ClinicalTrials.gov.
- 06 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 10 Sep 2008 New trial record.